| Title |
Cost-Effectiveness Analysis of Prognostic Gene Expression Signature-Based Stratification of Early Breast Cancer Patients
|
|---|---|
| Published in |
PharmacoEconomics, November 2014
|
| DOI | 10.1007/s40273-014-0227-x |
| Pubmed ID | |
| Authors |
Patricia R. Blank, Martin Filipits, Peter Dubsky, Florian Gutzwiller, Michael P. Lux, Jan C. Brase, Karsten E. Weber, Margaretha Rudas, Richard Greil, Sibylle Loibl, Thomas D. Szucs, Ralf Kronenwett, Matthias Schwenkglenks, Michael Gnant |
| Abstract |
The individual risk of recurrence in hormone receptor-positive primary breast cancer patients determines whether adjuvant endocrine therapy should be combined with chemotherapy. Clinicopathological parameters and molecular tests such as EndoPredict(®) (EPclin) can support decision making in patients with estrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative cancer. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 117 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | <1% |
| Unknown | 116 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 24 | 21% |
| Student > Ph. D. Student | 17 | 15% |
| Student > Bachelor | 12 | 10% |
| Student > Master | 11 | 9% |
| Other | 11 | 9% |
| Other | 22 | 19% |
| Unknown | 20 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 41 | 35% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 6% |
| Nursing and Health Professions | 6 | 5% |
| Agricultural and Biological Sciences | 5 | 4% |
| Economics, Econometrics and Finance | 5 | 4% |
| Other | 24 | 21% |
| Unknown | 29 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 March 2017.
All research outputs
#6,408,907
of 22,770,070 outputs
Outputs from PharmacoEconomics
#712
of 1,816 outputs
Outputs of similar age
#89,601
of 362,492 outputs
Outputs of similar age from PharmacoEconomics
#10
of 26 outputs
Altmetric has tracked 22,770,070 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 1,816 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one has gotten more attention than average, scoring higher than 59% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 362,492 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
We're also able to compare this research output to 26 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 57% of its contemporaries.